Does perioperative electroacupuncture reduce the incidence of atrial fibrillation after lung cancer surgery? A randomized, controlled, assessor-blinded clinical trial.

IF 3.1 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Frontiers in Medicine Pub Date : 2025-05-12 eCollection Date: 2025-01-01 DOI:10.3389/fmed.2025.1565359

Zheng-Qing Zhou, Yi-Jing Chen, Hua Xu

{"title":"Does perioperative electroacupuncture reduce the incidence of atrial fibrillation after lung cancer surgery? A randomized, controlled, assessor-blinded clinical trial.","authors":"Zheng-Qing Zhou, Yi-Jing Chen, Hua Xu","doi":"10.3389/fmed.2025.1565359","DOIUrl":null,"url":null,"abstract":"Background: Atrial fibrillation (AF) is a common complication of lung cancer surgery, with high incidence during the perioperative period. Electroacupuncture is considered a potential complementary therapy for the management of AF. We aimed to evaluate the preventive effects of perioperative electroacupuncture on new-onset AF in patients undergoing lung cancer surgery.Methods: This was a single-center, randomized, controlled, assessor-blinded clinical trial. We randomly divided 90 patients with cancer who underwent lung surgery into an electroacupuncture group (EA) and a sham electroacupuncture group (SA). Four acupuncture points on the surgical side were selected for the intervention. The EA group was needled with an EA instrument using sparse and dense waves alternating at 2/100 Hz. Electroacupuncture treatments were administered thrice. The incidence of newly developed AF within 72 h after surgery was used as the main indicator, and the Visual Analog Scale, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and blood levels of Interleukin-6 (IL-6) were used as secondary outcomes.Results: The EA group showed a 14.6% absolute risk reduction in POAF incidence compared to the SA group (P = 0.013). NT-proBNP level (MD: +32.57 pg/mL, 95% CI: 5.8-59.3, P = 0.018) and interleukin-6 level (MD: +9.29 pg/mL, 95% CI: 1.45-17.1, P = 0.021) increased significantly in the SA group compared to the EA group at 72h. No significant differences were observed in VAS scores (12 h: MD -0.27, 95% CI: -0.8 to 0.2, P = 0.572; 72h: MD -0.50, 95% CI: -0.4 to 0.3, P = 0.238).Conclusion: This study confirmed that electroacupuncture reduced the incidence of new-onset AF in the perioperative period, providing a possible complementary therapy for the prevention of arrhythmia after lung cancer surgery.Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=127920, identifier ChiCTR2100047499.","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1565359"},"PeriodicalIF":3.1000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12104173/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1565359","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Atrial fibrillation (AF) is a common complication of lung cancer surgery, with high incidence during the perioperative period. Electroacupuncture is considered a potential complementary therapy for the management of AF. We aimed to evaluate the preventive effects of perioperative electroacupuncture on new-onset AF in patients undergoing lung cancer surgery.

Methods: This was a single-center, randomized, controlled, assessor-blinded clinical trial. We randomly divided 90 patients with cancer who underwent lung surgery into an electroacupuncture group (EA) and a sham electroacupuncture group (SA). Four acupuncture points on the surgical side were selected for the intervention. The EA group was needled with an EA instrument using sparse and dense waves alternating at 2/100 Hz. Electroacupuncture treatments were administered thrice. The incidence of newly developed AF within 72 h after surgery was used as the main indicator, and the Visual Analog Scale, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and blood levels of Interleukin-6 (IL-6) were used as secondary outcomes.

Results: The EA group showed a 14.6% absolute risk reduction in POAF incidence compared to the SA group (P = 0.013). NT-proBNP level (MD: +32.57 pg/mL, 95% CI: 5.8-59.3, P = 0.018) and interleukin-6 level (MD: +9.29 pg/mL, 95% CI: 1.45-17.1, P = 0.021) increased significantly in the SA group compared to the EA group at 72h. No significant differences were observed in VAS scores (12 h: MD -0.27, 95% CI: -0.8 to 0.2, P = 0.572; 72h: MD -0.50, 95% CI: -0.4 to 0.3, P = 0.238).

Conclusion: This study confirmed that electroacupuncture reduced the incidence of new-onset AF in the perioperative period, providing a possible complementary therapy for the prevention of arrhythmia after lung cancer surgery.

Clinical trial registration: https://www.chictr.org.cn/showproj.html?proj=127920, identifier ChiCTR2100047499.

查看原文本刊更多论文

围手术期电针能降低肺癌术后房颤的发生率吗？一项随机、对照、评估盲法临床试验。

背景：心房颤动（AF）是肺癌手术常见的并发症，在围手术期发病率较高。电针被认为是治疗房颤的一种潜在的辅助疗法。我们旨在评估围手术期电针对肺癌手术患者新发房颤的预防作用。方法：这是一项单中心、随机、对照、评估盲法临床试验。我们将90例接受肺部手术的癌症患者随机分为电针组（EA）和假电针组（SA）。选择手术侧4个穴位进行干预。电休克组用电休克仪针刺，以2/100 Hz频率交替使用稀疏波和密集波。电针治疗三次。以术后72 h内新发房颤发生率为主要指标，以视觉模拟量表、n端前b型利钠肽（NT-proBNP）、血白细胞介素-6 （IL-6）水平为次要指标。结果：与SA组相比，EA组POAF发生率绝对风险降低14.6% （P = 0.013）。72h SA组NT-proBNP水平（MD: +32.57 pg/mL, 95% CI: 5.8 ~ 59.3, P = 0.018）和白细胞介素-6水平（MD: +9.29 pg/mL, 95% CI: 1.45 ~ 17.1, P = 0.021）较EA组显著升高。两组VAS评分差异无统计学意义(12 h: MD -0.27, 95% CI: -0.8 ~ 0.2, P = 0.572；72h: MD -0.50, 95% CI: -0.4 ~ 0.3, P = 0.238)。结论：本研究证实电针可降低围手术期新发房颤的发生率，为预防肺癌术后心律失常提供了一种可能的辅助疗法。临床试验注册：https://www.chictr.org.cn/showproj.html?proj=127920，标识符ChiCTR2100047499。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Medicine Medicine-General Medicine

CiteScore

5.10

自引率

5.10%

发文量

3710

审稿时长

12 weeks

期刊介绍： Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world